These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 26511823)

  • 1. Resin lacquer: a cheaper alternative to amorolfine for onychomycosis?
    Yong AS
    Br J Dermatol; 2015 Oct; 173(4):888-9. PubMed ID: 26511823
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of topical resin lacquer, amorolfine and oral terbinafine for treating toenail onychomycosis: a prospective, randomized, controlled, investigator-blinded, parallel-group clinical trial.
    Auvinen T; Tiihonen R; Soini M; Wangel M; Sipponen A; Jokinen JJ
    Br J Dermatol; 2015 Oct; 173(4):940-8. PubMed ID: 26036329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-reported outcomes from two randomised studies comparing once-weekly application of amorolfine 5% nail lacquer to other methods of topical treatment in distal and lateral subungual onychomycosis.
    Schaller M; Sigurgeirsson B; Sarkany M
    Mycoses; 2017 Dec; 60(12):800-807. PubMed ID: 28925059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of amorolfine nail lacquer for the prophylaxis of onychomycosis over 3 years.
    Sigurgeirsson B; Olafsson JH; Steinsson JT; Kerrouche N; Sidou F
    J Eur Acad Dermatol Venereol; 2010 Aug; 24(8):910-5. PubMed ID: 20028447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of onychomycosis with ciclopirox nail lacquer: a case report.
    Galitz J
    Cutis; 2001 Aug; 68(2 Suppl):23-4. PubMed ID: 11665725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ciclopirox nail lacquer solution 8% in the 21st century.
    Gupta AK; Baran R
    J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S96-102. PubMed ID: 11051138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter, randomized, open-label, controlled study comparing the efficacy, safety and cost-effectiveness of a sequential therapy with RV4104A ointment, ciclopiroxolamine cream and ciclopirox film-forming solution with amorolfine nail lacquer alone in dermatophytic onychomycosis.
    Paul C; Coustou D; Lahfa M; Bulai-Livideanu C; Doss N; Mokthar I; Turki H; Nouira R; Fazaa B; Ben Osman A; Zourabichvili O; Cazeau C; Coubetergues H; Picot S; Bienvenu AL; Voisard JJ
    Dermatology; 2013; 227(2):157-64. PubMed ID: 24051622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dermatopharmacologic profile of ciclopirox 8% nail lacquer.
    Bohn M; Kraemer K
    J Am Podiatr Med Assoc; 2000; 90(10):491-4. PubMed ID: 11107709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical treatment of onychomycosis with amorolfine 5% nail lacquer: comparative efficacy and tolerability of once and twice weekly use.
    Reinel D
    Dermatology; 1992; 184 Suppl 1():21-4. PubMed ID: 1532336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case of infantile onychomycosis successfully cured by 5% amorolfine nail lacquer.
    Chen S; Ran YP; Dai YL; Lama J; Hu WY
    J Paediatr Child Health; 2014 Nov; 50(11):933-4. PubMed ID: 25376356
    [No Abstract]   [Full Text] [Related]  

  • 11. Ciclopirox nail lacquer and podiatric practice.
    Gupta AK; Malkin KF
    J Am Podiatr Med Assoc; 2000; 90(10):502-7. PubMed ID: 11107711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ciclopirox nail lacquer for the treatment of onychomycosis: an open non-comparative study.
    Shemer A; Nathansohn N; Trau H; Amichai B; Grunwald MH
    J Dermatol; 2010 Feb; 37(2):137-9. PubMed ID: 20175847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of amorolfine 5% nail lacquer in combination with systemic antifungal agents for onychomycosis: A meta-analysis and systematic review.
    Feng X; Xiong X; Ran Y
    Dermatol Ther; 2017 May; 30(3):. PubMed ID: 28097731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative clinical evaluation of efficacy and safety of a formulation containing ciclopirox 8% in the form of a therapeutic nail lacquer in two different posologies for the treatment of onychomycosis of the toes.
    Schalka S; Nunes S; Gomes Neto A
    An Bras Dermatol; 2012; 87(1):19-25. PubMed ID: 22481647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States.
    Gupta AK; Joseph WS
    J Am Podiatr Med Assoc; 2000; 90(10):495-501. PubMed ID: 11107710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ciclopirox 8% nail lacquer topical solution for the treatment of onychomycosis in patients with diabetes: a multicenter, open-label study.
    Brenner MA; Harkless LB; Mendicino RW; Page JC
    J Am Podiatr Med Assoc; 2007; 97(3):195-202. PubMed ID: 17507527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Onychomycosis does not always require systemic treatment for cure: a trial using topical therapy.
    Friedlander SF; Chan YC; Chan YH; Eichenfield LF
    Pediatr Dermatol; 2013; 30(3):316-22. PubMed ID: 23278851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of 5% amorolfine nail lacquer in Neoscytalidium dimidiatum onychomycosis.
    Bunyaratavej S; Leeyaphan C; Rujitharanawong C; Surawan TM; Muanprasat C; Matthapan L
    J Dermatolog Treat; 2016 Aug; 27(4):359-63. PubMed ID: 26471716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A clinical study for the treatment of onychomycosis patients using a novel ROS producing onychomycosis treatment when compared against 5% amorolfine topical lacquer to reduce the visible size of infected toenails.
    Ehrensberger M; Boal CWC; Brennan J; Barrett J; Makarus J; Callanan S; Spillane E; Patton T
    J Mycol Med; 2022 Aug; 32(3):101256. PubMed ID: 35219908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ciclopirox nail lacquer: a brush with onychomycosis.
    Gupta AK
    Cutis; 2001 Aug; 68(2 Suppl):13-6. PubMed ID: 11665723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.